Two patients in the TMZ + IFNβ + RT arm terminated protocol treatment during the concomitant period due to progression and adverse events (grade 3 anorexia and grade 2 erythema multiforme) and 12 patients terminated protocol treatment due to progression, adverse events and patient refusal with adverse events (7, 3, and 2 patients) in the interval between the concomitant and the maintenance treatments. The gene discussed is IFNB1; the disease is erythema multiforme.